

AGIOS PHARMACEUTICALS INC

Form S-8

February 07, 2014

As filed with the Securities and Exchange Commission on February 6, 2014

Registration No. 333-

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM S-8

REGISTRATION STATEMENT

*UNDER*

*THE SECURITIES ACT OF 1933*

**Agios Pharmaceuticals, Inc.**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**  
(State or Other Jurisdiction of

Incorporation or Organization)

**38 Sidney Street, 2nd Floor**

**26-0662915**  
(I.R.S. Employer

Identification No.)

**02139**

**Cambridge, MA**  
**(Address of Principal Executive Offices)**  
**2013 Stock Incentive Plan**  
**(Zip Code)**

**(Full Title of the Plan)**

**David P. Schenkein, M.D.**

**Chief Executive Officer**

**Agios Pharmaceuticals, Inc.**

**38 Sidney Street, 2nd Floor**

**Cambridge, MA 02139**

**(Name and Address of Agent For Service)**

**(617) 649-8600**

**(Telephone Number, Including Area Code, of Agent For Service)**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐

Accelerated filer ☐

Non-accelerated filer ☒ (Do not check if a smaller reporting company)

Smaller reporting company ☐

**CALCULATION OF REGISTRATION FEE**

| <b>Title of Securities<br/>to be Registered</b> | <b>Amount<br/>to be<br/>Registered (1)</b> | <b>Proposed<br/>Maximum<br/>Offering Price<br/>Per Share</b> | <b>Proposed<br/>Maximum<br/>Aggregate<br/>Offering Price</b> | <b>Amount of<br/>Registration Fee</b> |
|---|--|--|--|---------------------------------------|
|   |  |  |  |                                       |
| Common Stock, \$0.001 par value per share       | 1,242,966 shares                           | \$26.23 (2)  | \$32,602,998.18 (2)  | \$4,200                               |

- (1) In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.
- (2) Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act of 1933, as amended, and based upon the average of the high and low prices of the Registrant's Common Stock as reported on the Nasdaq Global Select Market on February 3, 2014.

**Statement of Incorporation by Reference**

This Registration Statement on Form S-8, relating to the 2013 Stock Incentive Plan of Agios Pharmaceuticals, Inc. (the Registrant ), is being filed for the purpose of registering additional securities of the same class as other securities for which a Registration Statement on Form S-8 has previously been filed and is effective. Accordingly, this Registration Statement incorporates by reference the contents of the Registration Statement on Form S-8, File No. 333-190101, filed with the Securities and Exchange Commission on July 24, 2013 by the Registrant, relating to the Registrant's 2007 Stock Incentive Plan, 2013 Stock Incentive Plan and 2013 Employee Stock Purchase Plan, except for Item 8, Exhibits, with respect to which the Exhibit Index immediately preceding the exhibits attached hereto is incorporated herein by reference.

## SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on this 6th day of February, 2014.

AGIOS PHARMACEUTICALS, INC.

By: /s/ David P. Schenkein  
David P. Schenkein, M.D.  
*Chief Executive Officer*

## POWER OF ATTORNEY AND SIGNATURES

We, the undersigned officers and directors of Agios Pharmaceuticals, Inc., hereby severally constitute and appoint David P. Schenkein, M.D., J. Duncan Higgons and Glenn Goddard and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Agios Pharmaceuticals, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

| Signature                | Title  | Date             |
|--------------------------|--|------------------|
| /s/ David P. Schenkein   | Chief Executive Officer and Director         | February 6, 2014 |
| David P. Schenkein, M.D. | (Principal executive officer)                |                  |
| /s/ Glenn Goddard        | Senior Vice President, Finance               | February 6, 2014 |
| Glenn Goddard            | (Principal financial and accounting officer) |                  |
| /s/ Lewis C. Cantley     | Director                                     | February 6, 2014 |
| Lewis C. Cantley, Ph.D.  |  |                  |
| /s/ Paul J. Clancy       | Director                                     | February 6, 2014 |
| Paul J. Clancy           |  |                  |
| /s/ Douglas G. Cole      | Director                                     | February 6, 2014 |

Douglas G. Cole, M.D.

---

|                             |          |                  |
|-----------------------------|----------|------------------|
| /s/ Perry Karsen            | Director | February 6, 2014 |
| Perry Karsen                |          |                  |
| /s/ John M. Maraganore      | Director | February 6, 2014 |
| John M. Maraganore, Ph.D.   |          |                  |
| /s/ Robert T. Nelsen        | Director | February 6, 2014 |
| Robert T. Nelsen            |          |                  |
| /s/ Kevin P. Starr          | Director | February 6, 2014 |
| Kevin P. Starr              |          |                  |
| /s/ Marc Tessier-Lavigne    | Director | February 6, 2014 |
| Marc Tessier-Lavigne, Ph.D. |          |                  |

## INDEX TO EXHIBITS

| Number  | Description  |
|---------|--|
| 4.1(1)  | Restated Certificate of Incorporation of the Registrant  |
| 4.2(1)  | Amended and Restated By-Laws of the Registrant   |
| 5.1     | Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Registrant  |
| 23.1    | Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1)   |
| 23.2    | Consent of Ernst & Young LLP, an independent registered public accounting firm   |
| 24.1    | Power of attorney (included on the signature pages of this registration statement)   |
| 99.1(2) | 2013 Stock Incentive Plan  |
| (1)     | Previously filed with the Securities and Exchange Commission as an Exhibit to the Registrant's Current Report on Form 8-K (File No. 001-36014) filed with the Securities and Exchange Commission on July 30, 2013 and incorporated herein by reference.                      |
| (2)     | Previously filed with the Securities and Exchange Commission as an Exhibit to the Registrant's Registration Statement on Form S-1, as amended (File No. 333-189216) filed with the Securities and Exchange Commission on June 24, 2013 and incorporated herein by reference. |